In the realm of bio/pharma, the impact of tariffs on rising costs and strained supply chains is a pressing concern. Companies are actively seeking ways to enhance compliance, diversify their sourcing, and secure stable trade conditions and R&D support. Recent survey results shed light on the challenges faced by the industry and the strategies being adopted to navigate the evolving regulatory landscape.
The survey, conducted by Pharmaceutical Technology® and Biopharm International® in August 2025, revealed that a significant majority of respondents perceive Trump-era tariffs as a major influence on their operations and supply chains. Nearly half of the participants reported significant effects, while another sizable segment anticipated moderate impacts. In response to these challenges, companies are adjusting their strategies by ramping up investments in trade compliance and broadening their supplier bases to mitigate risks effectively.
Tariffs are exerting the most significant impact on finished product trade, affecting various stages of the supply chain and regulatory processes. This disruption is prompting companies to strike a balance between reshoring, enhancing supply chain flexibility, and implementing regulatory mitigation measures. Looking ahead, there is an expectation that future administrations will likely moderate tariffs rather than eliminate them entirely, adding to the prevailing uncertainty that organizations are addressing through strategic readiness and adaptive trade approaches.
The survey findings underscore the industry’s need for policies that promote innovation, create stable trade environments, and ensure fair drug pricing. Companies are actively responding to the challenges posed by tariffs, with a focus on proactive measures such as diversifying sourcing, investing in domestic manufacturing, and applying for exclusions. While the prospect of reshoring is gaining traction, organizations are also prioritizing flexibility in their supply chains to mitigate risks effectively.
Key Takeaways:
– Tariffs are significantly impacting bio/pharma operations and supply chains, prompting companies to enhance compliance and diversify sourcing.
– Respondents emphasize the need for stable trade environments and policies that support innovation and fair drug pricing.
– Companies are adopting proactive measures like diversifying sourcing and investing in domestic manufacturing to navigate tariff challenges.
– The industry anticipates future administrations to moderate tariffs, highlighting the importance of adaptive trade strategies.
Tags: radiopharmaceuticals, regulatory, supply chain resilience, biopharma, pharmaceutical manufacturing
Read more on pharmtech.com